Page last updated: 2024-11-06

fenpipramide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fenpipramide: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65573
CHEMBL ID2106213
SCHEMBL ID149504
MeSH IDM0044121

Synonyms (37)

Synonym
nsc8005
1-piperidinebutanamide,.alpha.-diphenyl-
nsc-8005
fenpipramide
1-piperidinebutyramide,.alpha.-diphenyl-
77-01-0
hue 9980
.alpha.,.alpha.-diphenyl-1-piperidinebutyramide
nsc 8005
fempipramida [inn-spanish]
fenpipramidum [inn-latin]
1-piperidinebutanamide, alpha,alpha-diphenyl-
hoe 9980
brn 0281861
1-piperidinebutyramide, alpha,alpha-diphenyl-
alpha,alpha-diphenyl-1-piperidinebutyramide
fenpipramide [inn:ban]
2,2-diphenyl-4-piperidin-1-ylbutanamide
unii-88445508x3
4-20-00-01096 (beilstein handbook reference)
fenpipramidum
88445508x3 ,
fempipramida
CHEMBL2106213
fenpipramide [who-dd]
fenpipramide [inn]
fenpipramide [mart.]
SCHEMBL149504
DTXSID70227803
1-piperidinebutyramide, .alpha.,.alpha.-diphenyl-
1-piperidinebutanamide, .alpha.,.alpha.-diphenyl-
.alpha.,.alpha.-diphenyl-1-piperidinobutyramide
2,2-diphenyl-4-(1-piperidinyl)butanamide #
UETXPGADPCBQFT-UHFFFAOYSA-N
2,2-diphenyl-4-(piperidin-1-yl)butanamide
2,2-di(phenyl)-4-piperidin-1-ylbutanamide
Q27269890

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" Onset latencies and peak-to-peak amplitudes, elicited in the extensor carpi radialis and cranial tibial muscles, were analysed in 10 healthy Beagles that received either acepromazine or dexmedetomidine in combination with levomethadone/fenpipramide, in a crossover design."( Transcranial magnetic stimulation with acepromazine or dexmedetomidine in combination with levomethadone/fenpipramide in healthy Beagle dogs.
Amendt, HL; Kästner, SB; Rohn, K; Schütter, A; Siedenburg, JS; Söbbeler, FJ; Steffensen, N; Stein, VM; Tipold, A; Tünsmeyer, J, 2016
)
0.83

Dosage Studied

ExcerptRelevanceReference
"5, 1, 2, 4, 8, 12 and 24 hours after drug dosing in a separate occasion."( Contact heat thermal threshold testing in beagle dogs: baseline reproducibility and the effect of acepromazine, levomethadone and fenpipramide.
Hoffmann, MV; Kästner, SB; Kietzmann, M; Kramer, S, 2012
)
0.58
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1628464Intrinsic antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 isolate MRA-156 harboring CRT K76T mutant assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628465Intrinsic antimalarial activity against chloroquine/artemisinin-resistant Plasmodium falciparum ARS233 harboring CRT K76T mutant assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628462Intrinsic antimalarial activity against intermediate chloroquine-resistant Plasmodium falciparum 7G8 isolate MRA-154 harboring CRT SVMNT haplotype mutant assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628463Intrinsic antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 isolate MRA-159 harboring CRT CVIET haplotype mutant assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628461Intrinsic antimalarial activity against chloroquine-sensitive Plasmodium falciparum HB3 isolate MRA-155 assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628467Intrinsic antimalarial activity against chloroquine-resistant Plasmodium falciparum NHP4559 harboring CRT K76T mutant assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628449Inhibition of CRT CVIET haplotype mutant in Plasmodium falciparum K1 isolate MRA-159 infected in erythrocytes assessed as chloroquine-coumarin probe accumulation at 10 uM after 10 hrs by Hoechst 33342 staining based flow cytometry (Rvb = 35.57 +/- 3.84%)2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628460Intrinsic antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 isolate MRA-102 assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628466Intrinsic antimalarial activity against chloroquine/artemisinin-resistant Plasmodium falciparum ARS272 harboring CRT K76T mutant assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
AID1628468Intrinsic antimalarial activity against chloroquine/artemisinin-resistant Plasmodium falciparum NHP4773 harboring CRT K76T mutant assessed as reduction in parasite viability at 500 nM2016European journal of medicinal chemistry, Aug-25, Volume: 119Overcoming chloroquine resistance in malaria: Design, synthesis and structure-activity relationships of novel chemoreversal agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (25.00)18.7374
1990's1 (12.50)18.2507
2000's1 (12.50)29.6817
2010's4 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.96 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (25.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]